KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Goodwill (2020 - 2026)

Supernus Pharmaceuticals has reported Goodwill over the past 6 years, most recently at $124.9 million for Q4 2025.

  • Quarterly Goodwill rose 6.72% to $124.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $124.9 million through Dec 2025, up 6.72% year-over-year, with the annual reading at $124.9 million for FY2025, 6.72% up from the prior year.
  • Goodwill was $124.9 million for Q4 2025 at Supernus Pharmaceuticals, up from $119.1 million in the prior quarter.
  • Over five years, Goodwill peaked at $124.9 million in Q4 2025 and troughed at $77.9 million in Q1 2021.
  • The 5-year median for Goodwill is $117.0 million (2022), against an average of $111.5 million.
  • The largest YoY upside for Goodwill was 50.83% in 2021 against a maximum downside of 12.54% in 2021.
  • A 5-year view of Goodwill shows it stood at $117.5 million in 2021, then decreased by 0.42% to $117.0 million in 2022, then changed by 0.0% to $117.0 million in 2023, then changed by 0.0% to $117.0 million in 2024, then grew by 6.72% to $124.9 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Goodwill are $124.9 million (Q4 2025), $119.1 million (Q3 2025), and $117.0 million (Q2 2025).